Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer.
CONCLUSION: The dose perturbations introduced by the LFM were considerably smaller than the solid markers investigated. The RSP of the fiducial marker should be corrected in the treatment planning system to avoid errors. The investigated LFM introduced clinically acceptable dose perturbations for image-guided PBSPT of LALC.
PMID: 28104299 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Scherman Rydhög J, Perrin R, Jølck RI, Gagnon-Moisan F, Larsen KR, Clementsen P, Riisgaard de Blanck S, Fredberg Persson G, Weber DC, Lomax T, Andresen TL, Munck Af Rosenschold P Tags: Radiother Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Computers | Lung Cancer | PET Scan | Proton Therapy | Radiology